Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) is a pioneering clinical-stage gene therapy company committed to transforming the landscape of cancer and diabetes treatments. The company's mission is to address the unmet medical needs of a growing population of patients worldwide through the development of innovative immunogene therapies. Genprex's flagship product, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is at the forefront of its oncology program and is currently being evaluated in three clinical trials targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Oncoprex® Delivery System, Genprex's proprietary platform, encapsulates gene-expressing plasmids using lipid-based nanoparticles. This systemic, non-viral method enables the intravenous delivery of tumor suppressor genes to cancer cells, which then express proteins that were deficient in the tumor. Reqorsa Immunogene Therapy has shown promise by re-establishing pathways for programmed cell death, interrupting cancer cell signaling, and modulating immune responses.
The company's recent achievements include securing new patents and receiving FDA Fast Track and Orphan Drug designations for its clinical programs. Specifically, the Acclaim-2 and Acclaim-3 studies are exploring the potential of Reqorsa in combination with immune checkpoint inhibitors like Keytruda® and Tecentriq®. These trials aim to provide new therapeutic options for patients with advanced-stage lung cancers who have limited treatment alternatives.
In addition to its oncology initiatives, Genprex is advancing a novel gene therapy approach for diabetes. Using an AAV vector, the company delivers Pdx1 and MafA genes directly to the pancreas to transform alpha cells into beta-like cells capable of producing insulin. This method shows promise for both Type 1 and Type 2 diabetes and aims to offer a new lifeline for patients with these conditions.
Genprex collaborates with renowned institutions and industry leaders to further its research and development pipeline. The company's commitment to innovation and patient-centric solutions positions it as a significant player in the gene therapy landscape.
Latest News:
- March 12, 2024 - Genprex announces new patent grants in South Korea for Reqorsa® Immunogene Therapy.
- March 19, 2024 - Genprex enters into agreements for the sale and issuance of shares, expecting gross proceeds of $6.5 million.
- April 2, 2024 - Positive preclinical data for NPRL2 gene therapy presented at AACR Annual Meeting.
- April 3, 2024 - Multiple new trial sites added for Acclaim-3 study in extensive-stage small cell lung cancer.
- April 9, 2024 - Research collaborators present positive preclinical data supporting Reqorsa and NPRL2 therapies.
- May 8, 2024 - Genprex announces the passing of its co-founder and CEO Rodney Varner.
- May 14, 2024 - First patient dosed in Phase 1 of Acclaim-3 clinical study for Reqorsa® and Tecentriq® combination therapy.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Spring 2021 Oncology Investor Conference from March 29 to April 2, 2021. President and CEO Rodney Varner will deliver a virtual company overview on March 29 at 2 p.m. EDT, focusing on innovative gene therapies for non-small cell lung cancer and diabetes. Genprex's lead candidate, REQORSA™, has received Fast Track Designation by the FDA for treating NSCLC in combination with osimertinib, aiming to improve treatment options for patients with limited alternatives.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in two investor conferences in March 2021. The events are the Sachs 14th Annual European Life Sciences CEO Forum, taking place from March 10-12, and the 33rd Annual Roth Conference from March 15-17. Presentations will be led by CEO Rodney Varner, with availability for one-on-one meetings with investors. The presentations will be available for replay on the company's website following the events.
Genprex, Inc. (NASDAQ: GNPX) has announced a registered direct offering of 4,000,000 shares of common stock at $6.25 per share to institutional investors. The offering, priced at-the-market under Nasdaq rules, is expected to close on or around February 11, 2021, pending customary conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for this deal. No warrants will be issued. The company aims to utilize the funds to advance its clinical-stage gene therapy programs, specifically targeting cancers and diabetes.
Genprex, a clinical-stage gene therapy company focused on cancer and diabetes, has established a Clinical Advisory Board (CAB) to support its oncology and diabetes programs. This board is composed of leading clinical specialists who will guide the development of Genprex’s REQORSA™ immunogene therapy for non-small cell lung cancer and its diabetes gene therapy. CEO Rodney Varner emphasized the importance of the CAB's expertise in advancing clinical trials. Notable members include Dr. Michael Morse from Duke University and Dr. George E. Peoples, a veteran in cancer vaccine development.
Genprex, Inc. (NASDAQ: GNPX) supports World Cancer Day to raise global cancer awareness and promote equity in healthcare. CEO Rodney Varner emphasized the company's dedication to innovative oncology treatments for patients with limited options. Genprex's lead candidate, REQORSA™, possesses FDA Fast Track Designation for non-small cell lung cancer (NSCLC) treatment in combination with AstraZeneca's Tagrisso®. Upcoming Acclaim-1 and Acclaim-2 trials are set to begin in the first half of 2021, focusing on NSCLC therapies.
Genprex, Inc. (NASDAQ: GNPX) announced a corporate update detailing its progress and plans for 2021. The company is set to initiate two pivotal clinical trials for its gene therapy candidate, REQORSA™, targeting non-small cell lung cancer (NSCLC). The Acclaim-1 trial will combine REQORSA with Tagrisso® for patients whose disease progressed after Tagrisso treatment, while Acclaim-2 will combine it with Keytruda® for low PD-L1 expressors. Genprex also highlighted $40 million in capital raised in 2020, strengthening its financial position.
Genprex, Inc. (GNPX), a clinical-stage gene therapy company, announced its participation in the Virtual Investor Conference Small and Microcap Showcase on February 4, 2021. CEO Rodney Varner will present an overview, highlighting recent advancements in clinical trials. The event starts at 11 a.m. EST, and the presentation will be available for replay on the company’s website after the conference. Genprex focuses on gene therapies for cancer and diabetes, with its lead product, REQORSA™, currently evaluated for treating non-small cell lung cancer (NSCLC).
Genprex (GNPX), a clinical-stage gene therapy company, will present at the MoneyShow Accredited Investors Virtual Expo from January 26-28, 2021. CEO Rodney Varner is scheduled to provide a company overview and discuss recent advancements in clinical trials on January 28 at 12:25 p.m. EST. The presentation will be available for replay on Genprex's website afterwards. Genprex focuses on innovative therapies for cancer and diabetes, with its lead product candidate, REQORSA™, being evaluated for non-small cell lung cancer and having received Fast Track Designation from the FDA.
Genprex, Inc. (NASDAQ: GNPX) announced its participation in NobleCon17, the annual investor conference, on January 19-20. CEO Rodney Varner will present a company overview, with a focus on advancements in clinical trials, at 3:45 p.m. EST on January 19. A video webcast will be available for replay on the company's website post-conference. Notably, Genprex was highlighted in a recent Channelchek report as the most read research report of 2020. The company focuses on innovative gene therapies, including its lead candidate REQORSA™ for non-small cell lung cancer.
Genprex, Inc. (GNPX) announced successful completion of its first scaled-up clinical-grade manufacturing run of REQORSA™ immunogene therapy, essential for upcoming Acclaim-1 and Acclaim-2 clinical trials targeting non-small cell lung cancer (NSCLC). All specifications have been met, enabling supply delivery to clinical trial sites pending FDA approval. The technology transfer to commercial CDMOs has been successfully completed. The trials aim to evaluate REQORSA in combination with AstraZeneca's Tagrisso® and Merck's Keytruda®, initiating in the first half of 2021.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
What is Genprex's main focus?
What is Reqorsa Immunogene Therapy?
How does the Oncoprex® Delivery System work?
What recent achievements has Genprex made?
What is the status of Genprex's clinical trials?
What are the implications of Genprex's recent patent grants?
What is Genprex's approach to diabetes treatment?
How does Reqorsa enhance current cancer treatments?
Who are Genprex's key collaborators?
How has Genprex adapted to recent leadership changes?
